Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The CCTG BR31 (NCT02273375) trial, A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer has been closed to accrual to the main study.
The purpose of this study was to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
CCTG and its scope of research has been deemed an essential service by Queen’s University and we continue to be operational for our sites and trial patients. Given the critical nature of our research, we continue to monitor our activities and how trial adjustments can be made to ensure that patients can be managed on protocols.
The CCTG Operations and Statistics Centre has successfully completed the transition to a remote work environment with a small number of support staff in the offices.
As the COVID-19 situation continues to evolve, CCTG is closely monitoring the situation in consultation with our network of investigators and trial staff. The CCTG Operations and Statistical Centre remains operational and has full capabilities to support trial develop and oversight of the current portfolio.For the safety of our community we have completed a transition to remote work for our staff.
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19).
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19). After careful consideration and evaluation of available information at this time, and out of an abundance of caution for the entire network, the CCTG Annual Spring Meeting for 2020 is cancelled.
CCTG Network Members,
CCTG is actively monitoring the continuing developments pertaining to the coronavirus (COVID-19) . This includes reviewing reliable sources of information nationally and internationally as well as tracking travel restrictions. We are evaluating risks to patient safety, trial conduct and integrity, as well as critical meetings and engagement activities across the network. Safety and security are our top priorities as we review the situation.
The purpose of this study was to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects the study drugs has on this type of cancer.
Trial closures for BR16 (NCT00008385) trial: Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage 1 Non-Small Cell Lung Cancer and IND222 ( NCT02619864) A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme.
